- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04969978
Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation (CONNECT)
CONNECT: COmpreheNsive TraiNing and Engagement in Cessation Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Implement a Quitline electronic (e)Referral system with enhanced academic detailing (AD) (intervention; n=10 community health centers [CHCs]) and without enhanced AD (comparison; n=10 CHCs) to compare rates of eReferral offers, eReferral acceptance, Quitline enrollment, orders for smoking cessation medication, and receipt of in-clinic counseling among patients identified as current smokers.
II. Assess the effectiveness of implementing a Quitline eReferral system with enhanced AD (intervention) versus without enhanced AD (comparison) on self-reported smoking quit rates among all patients identified as current smokers using electronic health record (EHR) data.
III. Estimate the total annual costs and incremental cost-effectiveness of a Quitline eReferral system, with and without enhanced AD.
OUTLINE: Clinics are randomized to 1 of 2 arms.
ARM I: Clinics are notified via email that the eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding electronic health record (EHR) screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR. Clinics also gain access to technological assistance, as needed.
ARM II: Clinics receive standard online materials and access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the Quitline eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- OHSU Knight Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Study Clinic Inclusion Criteria:
- In Oregon
- On the OCHIN Epic EHR for >= 1 year
- Willing to be randomized to the intervention or comparison condition
- Willing to recruit a provider to serve as a clinic champion (to share monthly performance audit and feedback at all-staff meetings, determine desired content of booster sessions with clinic team members, and complete a survey at the completion of the intervention period) and a clinic manager to coordinate training and booster sessions
Study Patient Inclusion Criteria:
- Adult patients (>= 18 years of age)
- Identified as current tobacco users during >= 1 ambulatory and/or telehealth visit to one of the eligible study clinics over the 24-month study period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (Quitline eReferral)
Clinics are notified via email that the Quitline eReferral system is available with a link to an online publication that includes an overview of Quitline services, information on Quitline effectiveness, and a detailed eReferral workflow with corresponding EHR screenshots, including how to identify eligible patients, create an eReferral, and access Quitline follow-up data in the EHR.
Clinics also gain access to technological assistance, as needed.
|
Receive overview of Quitline services and use of Quitline eReferral via online materials
|
Experimental: ARM II (Quitline eReferral plus enhanced AD)
Clinics receive standard online materials access to remote technological assistance as in Arm I. Clinics also receive group training of clinic staff prior to activation of the eReferral system and 12 months post-activation, follow-up booster sessions and monthly performance audit and feedback.
|
Receive overview of Quitline services and use of Quitline eReferral via online materials
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Accepted electronic (e)Referral to Quitline
Time Frame: At any point during the 24-month intervention period
|
Proportion of patients who were offered and accepted the Quitline eReferral in intervention (EAD) versus comparator clinics.
Will use a logistic mixed effects model that addresses the following design features of the study: 1) will include random intercepts for providers and clinic to account for clustering of patients within providers within clinics; 2) will perform an intent-to-treat analysis; 3) hypothesis tests will be two-sided.
|
At any point during the 24-month intervention period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quitline eReferral offered
Time Frame: At any point during the 24-month intervention period
|
Proportion of patients who were offered the Quitline eReferral in intervention (EAD) versus comparator clinics.
Will construct similar logistic mixed effects models.
|
At any point during the 24-month intervention period
|
Quitline enrollment
Time Frame: At any point during the 24-month intervention period
|
Proportion of patients who were offered the Quitline eReferral and enrolled in Quitline services in intervention (EAD) versus comparator clinics.
Will construct similar logistic mixed effects models.
|
At any point during the 24-month intervention period
|
Receipt of in-office counseling
Time Frame: At any point during the 24-month intervention period
|
Proportion of patients with an indication in the electronic health record (EHR) of receipt of counseling during an office visit in intervention (EAD) versus comparator clinics.
Will construct similar logistic mixed effects models.
|
At any point during the 24-month intervention period
|
Smoking cessation medication ordered
Time Frame: At any point during the 24-month intervention period
|
Proportion of patients with a smoking cessation medication in the 'medication orders' list of the EHR in intervention (EAD) versus comparator clinics.
Will construct similar logistic mixed effects models.
|
At any point during the 24-month intervention period
|
Smoking cessation
Time Frame: At any point during the 24-month intervention period or up to 6 months post-intervention
|
Proportion of patients with EHR status change from current to former smoker.
Will utilize similar generalized linear mixed model (GLMM) modeling to estimate the impact of the intervention on cessation outcomes.
|
At any point during the 24-month intervention period or up to 6 months post-intervention
|
Annual intervention costs
Time Frame: Years 1-4
|
Mean total annual costs in years 1-4 to implement the eReferral into the EHR and maintain eReferral system, with and without enhanced academic detailing.
|
Years 1-4
|
Cost-effectiveness
Time Frame: Years 1-4
|
Mean total annual costs over years 1-4 by study arm, overall and for patients enrolled in the Quitline.
|
Years 1-4
|
Incremental cost-effectiveness ratio
Time Frame: Years 1-4
|
Difference in total costs by study arm, overall and for patients enrolled in Quitline.
|
Years 1-4
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tobacco use assessed
Time Frame: At any point during the 24-month intervention period
|
Proportion of patients who had a current tobacco use assessment in intervention (EAD) versus comparator clinics.
|
At any point during the 24-month intervention period
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Steffani Bailey, OHSU Department of Family Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- STUDY00023019 (OHSU Knight Cancer Institute)
- NCI-2021-06581 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- R01CA255016 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking Cessation
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
Nabi BiopharmaceuticalsNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco CessationUnited States
-
Claremont Graduate UniversityNational Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, CigaretteUnited States
-
Heidelberg UniversityPfizerTerminatedSmoking | Smoking Cessation | Tobacco Use CessationGermany
-
Mayo ClinicNational Institute on Drug Abuse (NIDA)CompletedSmoking | Smoking Cessation | Tobacco Use | Tobacco Smoking | Tobacco Use Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of MiamiFlorida Department of HealthRecruitingSmoking Cessation | Tobacco Smoking | Tobacco Use CessationUnited States
-
University of VermontMayo Clinic; Alaska Native Tribal Health ConsortiumTerminatedSmoking | Smoking CessationUnited States
-
University of Wisconsin, MadisonCentiment LLCCompletedSmoking | Smoking CessationUnited States
-
Yale UniversityCompletedSmoking | Smoking CessationUnited States
-
Johns Hopkins UniversityMaryland Department of Health and Mental HygieneCompletedCOach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation (C2Q)Smoking | Smoking CessationUnited States
Clinical Trials on Informational Intervention
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingCarcinoma | Malignant Neoplasm | Surgical Procedure, Unspecified | Health Care ProviderUnited States
-
The Miriam HospitalNational Institute of Mental Health (NIMH); University of Rochester; Syracuse...CompletedHIV Infections | Sexually Transmitted DiseasesUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNational Cancer Institute (NCI); Oregon Health and Science University; Kaiser... and other collaboratorsCompletedBreast Carcinoma | Cervical Carcinoma | Colorectal Carcinoma | Malignant Neoplasm | Human Papillomavirus Infection | Health Status UnknownUnited States
-
University of Alabama at BirminghamNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Cancer | Hot FlashesUnited States
-
Medical University of South CarolinaAlliance NCORP Research Base Cancer Control ProgramNot yet recruitingSmoking Cessation | Cancer
-
The Alternative Sexualities Health Research AllianceRecruitingPre-Exposure ProphylaxisUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingBRCA1 Gene Mutation | BRCA2 Gene MutationUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingClinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage 0 Cutaneous Melanoma AJCC v8 | Clinical Stage I Cutaneous Melanoma AJCC v8 | Clinical Stage IA Cutaneous Melanoma AJCC v8 | Clinical... and other conditionsUnited States